Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
33 results about "Primary isolate" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Primary isolate is a pure microbial or viral sample that has been obtained from an infected individual, rather than grown in a laboratory. In chemistry and bacteriology, the verb isolate means to obtain a pure chemical, bacteriological or viral sample. The noun 'isolate' refers to the sample itself.
Methods for using resonance energy transfer-based assay of HIV-1 envelope glycoprotein-mediated membrane fusion, and kits for practicing same
This invention provides: agents determined to be capable of specifically inhibiting the fusion of a macrophage-tropic primary isolate of HIV-1 to a CD4+ cell, but not a T cell-tropic isolate of HIV-1 to a CD4+ cell; and agents determined to be capable of specifically inhibiting the fusion of a T cell-tropic isolate of HIV-1 to a CD4+ cell, but not a macrophage-tropic primary isolate of HIV-1 to a CD4+ cell. This invention also provides: agents capable of specifically inhibiting the fusion of a macrophage tropic primary isolate of HIV-1 with a CD+ cell susceptible to infection by a macrophage-tropic primary isolate of HIV-1; and agents capable of specifically inhibiting the fusion of a T cell-tropic isolate of HIV-1 with a CD4+ cell susceptible to infection by a T cell-tropic isolate of HIV-1. The agents include but are not limited to antibodies. This invention further provides: methods of inhibiting fusion of a macrophage-tropic primary isolate of HIV-1 with a CD+ cell susceptible to infection by a macrophage-tropic primary isolate of HIV-1 which comprises contacting the CD4+ cell with an amount of an agent capable of specifically inhibiting such fusion so as to thereby inhibit such fusion; and methods of inhibiting fusion of a T cell-tropic isolate of HIV-1 with a CD4+ cell susceptible to infection by a T cell-tropic isolate of HIV-1 which comprises contacting the CD4+ cell with an amount of an agent capable of specifically inhibiting such fusion so as to thereby inhibit such fusion.
Owner:CYTODYN
INDUCTION OF BROADLY REACTIVE NEUTRALIZING ANTIBODIES BY FOCUSING THE IMMUNE RESPONSE ON V3 EPITOPES OF THE HIV-1 gp120 ENVELOPE
InactiveUS20080279879A1Vigorous Ab responseViral antigen ingredientsAntibody mimetics/scaffoldsHeterologousNeutralizing antibody
Compositions, kits and methods for boosting, or for priming and boosting, high titer broadly neutralizing cross-clade antibody responses focused on single HIV-1 neutralizing epitopes are disclosed. gp120 DNA plasmids comprising HIV env genes are used to prime the antibody response. Primed subjects are immunized with recombinant fusion proteins that comprise a “carrier” protein fusion partner, preferably a truncated form of the MuLV gp70 Env protein, and a desired HIV neutralizing epitopes. Preferred epitopes are epitopes of V3 from one or more HIV clades. Immune sera from such immunized subjects neutralized primary isolates from virus strains heterologous to those from which the immunogens were constructed. Neutralizing activity was primarily due to V3-specific antibodies and cross-clade neutralizing Abs were present. This approach results in more potent and broader neutralizing antibody levels, a result of “immunofocusing” the humoral immune response on neutralizing epitopes such as V3.
Owner:NEW YORK UNIV
Consensus/ancestral immunogens
The present invention relates, in general, to an immunogen and, in particular, to an immunogen for inducing antibodies that neutralizes a wide spectrum of HIV primary isolates and / or to an immunogen that induces a T cell immune response. The invention also relates to a method of inducing anti-HIV antibodies, and / or to a method of inducing a T cell immune response, using such an immunogen. The invention further relates to nucleic acid sequences encoding the present immunogens.
Owner:UNIVERSITY OF ALABAMA +2
Nucleic acids encoding modified human immunodeficiency virus type 1 (HIV-1) group M consensus envelope glycoproteins
The present invention relates, in general, to an immunogen and, in particular, to an immunogen for inducing antibodies that neutralizes a wide spectrum of HIV primary isolates and / or to an immunogen that induces a T cell immune response. The invention also relates to a method of inducing anti-HIV antibodies, and / or to a method of inducing a T cell immune response, using such an immunogen. The invention further relates to nucleic acid sequences encoding the present immunogens.
Owner:UNIVERSITY OF ALABAMA +2
Methods for assaying inhibition of HIV-1 envelope glycoprotein-mediated membrane fusion
Owner:PROGENICS PHARMA INC
Modified HIV-1 clade C envelope glycoprotein immunogens comprising deletions in the gp120/gp41 cleavage site and gp41 fusion domain
The present invention relates, in general, to an immunogen and, in particular, to an immunogen for inducing antibodies that neutralize a wide spectrum of HIV primary isolates and / or to an immunogen that induces a T cell immune response. The invention also relates to a method of inducing anti-HIV antibodies, and / or to a method of inducing a T cell immune response, using such an immunogen. The invention further relates to nucleic acid sequences encoding the present immunogens.
Owner:DUKE UNIV
Primary isolated culture method for dairy cow mammary epithelial cells
InactiveCN105543164AReduced activityShorten the timeCell dissociation methodsEpidermal cells/skin cellsHyaluronidaseMammary gland structure
The invention discloses a primary isolated culture method for dairy cow mammary epithelial cells. The primary isolated culture method comprises steps as follows: mammary tissue of a dairy cow in the lactation period is shorn into tissue blocks, the tissue blocks are digested with collagenase / hyaluronidase digestive juice, a culture dish is inoculated with the digested chylous tissue blocks for culture, cells get free from tissue on peripheries of the tissue blocks after 1-2 days and grow along the wall of the culture dish, fusiform fibroblast is removed with a mechanical scraping method every day during culture, and initial passage is performed when a large quantity of cobblestone-like mammary epithelial cells grow in clusters and in patches and are mutually fused after about 4-5 days. During initial passage, a little fibroblast which is probably mixed is eliminated with trysin with a differential digestive method, and the dairy cow mammary epithelial cells with high purity are obtained. The mammary epithelial cells can emigrate from chylous tissue in a short time; a little mixed fibroblast is removed mainly with a mechanical scraping method, and accordingly, the obtained mammary epithelial cells are seldom damaged and are high in purity.
Owner:NORTHWEST A & F UNIV
Isolated culture method of porcine fat stem cells
InactiveCN104673745AEasy to isolate and cultureStrong proliferative growth abilitySkeletal/connective tissue cellsAnimal sciencePhosphate
The invention discloses an isolated culture method of porcine fat stem cells, which comprises the following steps: extracting porcine subcutaneous fat tissues, washing the fat tissues with a double-antibody-containing PBS (phosphate buffer solution), adding a I-type collagenase digestive juice into the fat tissues for digestion to obtain porcine fat stem cells, and culturing in an EGF-containing serum-free culture medium. The porcine fat stem cell isolated culture method can reduce the influence of blood and other impurities in the fat tissue source on the enzymolysis fat and shorten the fat enzymolysis time of the I-type collagenase; the serum-free culture medium is utilized to culture the primary cells; and proper growth factors are added into the culture medium, so that the porcine fat stem cells can be better subjected to isolated culture and maintain high proliferation and growth capacity, thereby establishing a porcine fat stem primary isolated culture method conforming to the Standard Specification.
Owner:GUANGZHOU SALIAI STEMCELL SCI & TECH CO LTD
Consensus/ancestral immunogens
InactiveUS20090162384A1Viral antigen ingredientsSnake antigen ingredientsNucleic acid sequencingT cell immunity
The present invention relates, in general, to an immunogen and, in particular, to an immunogen for inducing antibodies that neutralize a wide spectrum of HIV primary isolates and / or to an immunogen that induces a T cell immune response. The invention also relates to a method of inducing anti-HIV antibodies, and / or to a method of inducing a T cell immune response, using such an immunogen. The invention further relates to nucleic acid sequences encoding the present immunogens.
Owner:DUKE UNIV
Designed deimmunized monoclonal antibodies for protection against HIV exposure and treatment of HIV infection
ActiveUS7501494B2Low costProphylaxis of HIV exposureAntiviralsImmunoglobulins against cell receptors/antigens/surface-determinantsDiseaseImmunodeficiency virus
This invention is directed to deimmunized antibodies that are useful as immunotherapeutic drugs against Human Immunodeficiency Virus (HIV) and CD4-mediated autoimmune disorders. More specifically, antibodies expressed by clones, Clone 7 containing the recombinant genes B4DIVHv1 / VK1CHO#7, Clone 16 containing the recombinant genes B4DIVHv1 / VK1#16, and clone 21 containing the recombinant genes B4DIVHv1 / VK1#21, are derived from mouse monoclonal B4 antibody (mAb B4). The antibodies were produced by removing particular murine determinants recognized as foreign by the human immune system. These recombinant antibodies were generated by the chimerization and deimmunization of the Fv region of mouse monoclonal antibody (mAb) B4. For improved safety, the coding sequence may further be mutated to express an aglycosylated IgG1 antibody that is unable to bind complement. The deimmunized antibodies retain the specificity of the murine mAb B4 for a receptor complex involving CD4 on the surface of the host T cells, and retain the characteristic ability of mAb B4 to neutralize primary isolates of HIV.
Owner:UBI US HLDG LLC
Deimmunized monoclonal antibodies for protection against HIV exposure and treatment of HIV infection
InactiveUS20090060914A1Low costMass productionAnimal cellsSugar derivativesDiseaseImmunodeficiency virus
This invention is directed to deimmunized antibodies that are useful as immunotherapeutic drugs against Human Immunodeficiency Virus (HIV) and CD4-mediated autoimmune disorders. More specifically, antibodies expressed by clones, Clone 7 containing the recombinant genes B4DIVHv1 / VK1CHO#7, Clone 16 containing the recombinant genes B4DIVHv1 / VK1#16, and clone 21 containing the recombinant genes B4DIVHv1 / VK1#21, are derived from mouse monoclonal B4 antibody (mAb B4). The antibodies were produced by removing particular murine determinants recognized as foreign by the human immune system. These recombinant antibodies were generated by the chimerization and deimmunization of the Fv region of mouse monoclonal antibody (mAb) B4. For improved safety, the coding sequence may further be mutated to express an aglycosylated IgG1 antibody that is unable to bind complement. The deimmunized antibodies retain the specificity of the murine mAb B4 for a receptor complex involving CD4 on the surface of the host T cells, and retain the characteristic ability of mAb B4 to neutralize primary isolates of HIV.
Owner:UBI US HLDG LLC
Freezing medium, application thereof and adipose tissue freezing method
InactiveCN106719602AImprove protectionHigh activityDead animal preservationCell activityEssential amino acid
The invention relates to the technical field of cells, in particular to a freezing medium, application thereof and an adipose tissue freezing method. The freezing medium comprises a basic culture solution, an NEAA (non-essential amino acid), DMSO, glycerol and 1,2-propanediol, and has a good protection effect on adipose tissue. Cells in adipose tissue which is thawed after being frozen by the freezing medium keep good activity. The success rate of obtaining adipose-derived stem cells by primary isolated culture is 100 percent.
Owner:GUANGZHOU SALIAI STEMCELL SCI & TECH CO LTD
Fibroblasts derived from multiple tissue sources of native dog through primary isolated culture and immortalization construction method of fibroblasts
PendingCN112574946AHigh activitySimple and fast operationCell dissociation methodsArtificial cell constructsDiseaseMuscle tissue
The invention provides fibroblasts derived from multiple tissue sources of a native dog through primary isolated culture and an immortalization construction method of the fibroblasts, and belongs to the technical field of cell culture. Heart tissue, lung tip muscle tissue or leg muscle tissue of the native dog are used as materials and subjected to enzymolysis and separation of pancreatin and / or collagenase II, and myocardial fibroblasts, lung fibroblasts and myofibroblasts with typical fibroblast morphological characteristics are obtained. The myocardial fibroblasts, the pulmonary fibroblastsand the myofibroblasts which are subjected to primary isolated culture are transfected by SV40T virus liquid, and then puromycin screening culture and passage are performed to obtain immortalized myocardial fibroblasts, pulmonary fibroblasts and myofibroblasts. Compared with primary culture cells, the immortalized constructed cells are higher in growth speed and remarkably improved in activity, and a material basis is provided for dogs in the aspects of scientific research, disease research and the like.
Owner:KUNMING INST OF ZOOLOGY CHINESE ACAD OF SCI
Primary isolated culture method for amniotic fluid mesenchymal stem cells
ActiveCN104830764AAvoid damageAvoid pollutionSkeletal/connective tissue cellsCulture fluidAmniotic fluid
The invention relates to the technical field of stem cell culture, in particular to a primary isolated culture method for amniotic fluid mesenchymal stem cells. The method includes that according to a differential attachment principle, endothelial cells are enabled to grow along a wall under proper conditions while the mesenchymal stem cells are not adhered to the wall yet. By accurate control of culture time, culture solution containing the amniotic fluid mesenchymal stem cells is transferred after wall adherence of the endothelial cells is finished, and the culture solution is subjected to subculturing to obtain the amniotic fluid mesenchymal stem cells. The method is simple in operation, less devices are required, manual scraping operations are avoided, and accordingly cell damages and contamination are avoided. According to detection results, viability of the amniotic fluid mesenchymal stem cells contained in the culture solution acquired at the step 1 is not lower than 89.28%; after three generations, flow cytometry detection results show that surface antibodies of the cells still accord with characteristics of the stem cells, and differentiating tendency is avoided.
Owner:GUANGZHOU SALIAI STEMCELL SCI & TECH CO LTD
Method for primary isolated culture of porcine mammary epithelial cells (PMEC)
InactiveCN112048465AAvoid complex environmentsCell dissociation methodsEpidermal cells/skin cellsDiseaseCultured cell
The invention relates to a method for primary isolated culture of porcine mammary epithelial cells (PMEC). The method includes the following steps: (1) performing sampling; (2) performing pretreatment; (3) performing isolation; (4) performing culture; (5) performing subculturing; and (6) performing cell purification. The beneficial effects of the method are as follows: complex environment in vivocan be avoided by establishing a porcine mammary epithelial cell model in vitro; researches on the influences of specific conditions and treatment on the growing status of cells can be carried out without being affected by individual difference; and mammary epithelial cell cultures can be taken as models to research bio-mechanism and disease mechanism in mammary gland organs.
Owner:陈浩东 +1
Immunizing against HIV infection
InactiveUS20020051770A1Improve the level ofReduce detectionBiocideGenetic material ingredientsAntigenEngineering
A virus neutralizing level of antibodies to a primary HIV isolate is generated in a host by a prime-boost administration of antigens. The primary antigen is a DNA molecule encoding an envelop glycoprotein of a primary isolate of HIV-1 while the boosting antigen is either a non-infectious, non-replicating HIV-like particle having the envelope glycoprotein of a primary isolate of HIV-1 or an attenuated viral vector expressing an envelope glycoprotein of a primary isolate of HIV-1.
Owner:AVENTIS PASTUER LTD
IGG1 monoclonal antibody with anti-HIV neutralizing activity
The present invention relates to neutralizing anti-HIV-1 antibodies, particularly to mAb 4E10-IgG1, which has an HIV-1 neutralizing potency comparable to the one of mAb 2F5 and 2G12. 4E10-IgG1 binds to a novel conserved epitope (NWFDIT) C-terminal of the ELDKWA epitope recognized by 2F5.1 appears that both epitopes are cryptic epitopes within a region that may be accessible in a virus-cell fusion intermediate state only. 4E10-IgG1 potently neutralizes tissue culture adapted strains but also primary isolates of different clades, including A, B, C, D, and E, inclusing viruses that were found to be resistant to 2F5. None of the tested isolates was resistant to both anti-gp41-antibodies. The invention therefore also relates to peptides containing the 4E10 epitope and to compositions made thereof, as well as to anti-idiotypic antibodies that are reactive with the paratope of 4E10-IgG1, to compositions containing an antiidiotypic antibody optionally in combination with a peptide containing the 4E10 epitope, and to anti-HIV-1 compositions comprising 4E10-IgG1, optionally in combination with another neutralizing antibody such as 2F5 and / or 2G12.
Owner:POLYMUN SCI IMMUNBIOLOGISCHE FORSCHUNG
Primary isolated culture and induced differentiation method for precursor fat cells in adult yak muscles
ActiveCN113717932AReduce difficultyLower acquisition costsCell dissociation methodsCulture processBiotechnologyGenes proteins
The invention discloses a primary isolated culture and induced differentiation method for precursor fat cells in adult yak muscles. The method comprises the steps of disinfection treatment and segmentation, digestion, screening and filtration, centrifugation, purification and culture. According to the cell culture for the precursor fat cells in the adult yak muscles, provided by the invention, manpower and material resources can be saved, and the limitation of high pollution rate caused by using newborn calf fat tissues and primary cells in a traditional culture method is broken through, so that the source approach of samples is wider, and a large number of cells can be obtained at the same time; and the culture method is a convenient and efficient precursor fat cell culture method, provides a molecular basis for subsequent in-depth research on gene and protein expression, signal channels and the like in proliferation and differentiation process of intramuscular precursor fat cells, provides a new thought and a new method for research on fat deposition, fat metabolism, fat mobilization and the like of different parts, and has an important significance in improving the meat quality of yaks.
Owner:SICHUAN AGRI UNIV
Hiv-1 peptides, nucleic acids, and compositions, and uses thereof
Owner:RUTGERS THE STATE UNIV
Immunizing against hiv infection
InactiveUS20040013684A1Improve the level ofReduce detectionViral antigen ingredientsVirus peptidesVirus-like particlePrime boost
A virus neutralizing level of antibodies to a primary HIV isolate is generated in a host by a prime-boost administration of antigents. The primary antigen is a DNA molecule encoding an envelop glycoprotein of a primary isolate of HIV-1 while the boosting antigen is either a non-infectious, non-replicating HIV-like particle having the envelope glycoprotein of a primary isolate of HIV-1 or an attenuated viral vector expressing an envelope glycoprotein of a primary isolate of HIV-1.
Owner:AVENTIS PASTEUR LTD
Hiv-1 gp41 neutralization domain and use thereof
InactiveUS20110091491A1Peptide/protein ingredientsAntibody mimetics/scaffoldsResistant virusMonoclonal antibody
The invention relates to a region of the HIV-I gp41 protein that contains, at least in part, an epitope that allows potent neutralization of resistant virus particles. This site is present in the C-terminal heptad repeat region of gp41 (HR2), and adjacent to, but distinct from the MPER. Vaccines containing this region as well as monoclonal antibodies which specifically bind to this region and neutralize an HIV-I primary isolate are also provided as is a method for stimulating the formation of antibodies that neutralize infection by an HIV isolate.
Owner:RUTGERS THE STATE UNIV
HIV-1 GP41 neutralization domain and use thereof
InactiveUS8475799B2Peptide/protein ingredientsAntibody mimetics/scaffoldsMonoclonal antibodyHeptad repeat
The invention relates to isolated monoclonal antibodies which specifically bind to the C-terminal heptad repeat region of gp41 (HR2) and neutralize an HIV-1 primary isolate.
Owner:RUTGERS THE STATE UNIV
Use of src protein inhibitor in the manufacture of a medicament for the prophylaxis and/or treatment of alzheimer's disease
The present invention provides use of a Src protein inhibitor N-(2-chloro-6-methylphenyl)-2-{6-[4-(3-hydroxyethyl)-1-piperazinyl]-2 -methyl-4-pyrimidinylamino}-5-thiazolecarboxamide (formula I) in the manufacture of a medicament for the prophylaxis and / or treatment of Alzheimer's disease. An Aβ42 oligomer and a tested drug were applied to primary isolated fetal mouse cerebral cortical neuron for 24 h to test the efficacy of the compound of formula I at different concentrations against Aβ42 oligomer toxicity in vitro, and the results show that the compound of formula I has a wide range of effective concentration and high cell viability at effective concentration.
Owner:JENKEM TECH
HIV-1 Peptides, Nucleic Acids, and Compositions and Uses Thereof
InactiveUS20110311569A1Avoid infectionVirus peptidesImmunoglobulins against virusesEpitopeNucleic acid sequencing
This invention features polypeptides, variants thereof, and fragments thereof useful in eliciting an immune response (e.g., neutralizing antibodies) against abroad spectrum of HIV-I isolates. The polypeptides, variants, and fragments include a portion of the gp120 V2 domain of HIV-I. The polypeptides, variants, and fragments display an epitope that is recognized by at least one antibody which neutralizes at least one HIV-I primary isolate. This invention also features nucleic acid sequences encoding those polypeptides. In addition, the invention provides methods of screening for inhibitors of HIV-I entry into cells, as well as methods of treatment using the inhibitors.
Owner:RUTGERS THE STATE UNIV
Isolated culture and subculture method of mouse breast cancer cells
PendingCN113817665AGuaranteed Nutritional SupportSimplified isolation and culture methodCell dissociation methodsEpidermal cells/skin cellsBiotechnologyDigestion Treatment
The invention discloses an isolated culture and subculture method of mouse breast cancer cells and belongs to the technical field of isolated culture methods of animal cells. The method comprises the following steps: cleaning in-vitro fresh mouse breast cancer tissue fragments subjected to pretreatment, and putting the cleaned in-vitro fresh mouse breast cancer tissue fragments into a collagenase I solution for digestive treatment; after the digestive treatment, adding culture, carrying out centrifuging, and reserving a precipitate; transferring the obtained precipitate into a culture bottle, carrying out culturing in an incubator, and beginning to change the liquid for the first time after carrying out culturing for 48 hours; after the culture is finished, removing non-adherent cells to obtain target cells; and replacing the culture medium, then, culturing the target cells, and after the target cells form a cell colony, obtaining subculturable mouse breast cancer cells. Under the condition of ensuring the purity of isolated culture of the primary cells, an isolated culture of the primary cells is shortened and simplified. According to the method, a frequent liquid change mode at an early stage of primary isolated culture in the prior art is adjusted to be complete liquid change for the first time in 48 hours, so that the liquid change frequency is greatly lowered.
Owner:哈尔滨中科赛恩斯生物技术有限公司
A method for isolating avian metapneumovirus
ActiveCN104911153BImprove in vitro culture conditionsImprove separation rateMicroorganism based processesViruses/bacteriophagesMixed cultureMetapneumovirus
The invention provides a method for isolating the avian metapneumovirus. The invention adopts the mixed cells of the trachea and lung tissue of hatched SPF chicken embryos aged 17 to 19 days to culture the avian metapneumovirus. On the basis of the traditional method of separating and culturing one clinically ill sample and one sensitive cell at a time, the present invention successfully improves the in vitro culture conditions of AMPV through the same culture system, the separation and passage method of two mixed cells, and significantly improves the separation of AMPV rate, reducing the number of passages.
Owner:YEBIO BIOENG OF QINGDAO
Primary isolation and culture method of amniotic fluid mesenchymal stem cells
ActiveCN104830764BAvoid damageAvoid pollutionSkeletal/connective tissue cellsCulture fluidAmniotic fluid
The invention relates to the technical field of stem cell culture, in particular to a primary isolated culture method for amniotic fluid mesenchymal stem cells. The method includes that according to a differential attachment principle, endothelial cells are enabled to grow along a wall under proper conditions while the mesenchymal stem cells are not adhered to the wall yet. By accurate control of culture time, culture solution containing the amniotic fluid mesenchymal stem cells is transferred after wall adherence of the endothelial cells is finished, and the culture solution is subjected to subculturing to obtain the amniotic fluid mesenchymal stem cells. The method is simple in operation, less devices are required, manual scraping operations are avoided, and accordingly cell damages and contamination are avoided. According to detection results, viability of the amniotic fluid mesenchymal stem cells contained in the culture solution acquired at the step 1 is not lower than 89.28%; after three generations, flow cytometry detection results show that surface antibodies of the cells still accord with characteristics of the stem cells, and differentiating tendency is avoided.
Owner:GUANGZHOU SALIAI STEMCELL SCI & TECH CO LTD
Preparation technique for high-purity hydrocortisone
The invention discloses a process for the separation and preparation of refined high-purity hydrocortisone, using low-toxic solvent dichloromethane instead of dichloroethane, one separation process in the process: the weight ratio of raw materials is crude hydrocortisone: dichloromethane Methane:methanol:water=1:6.6-11.9:1.68-3.16:3-3.5. Secondary separation process: the weight ratio of raw materials is hydrocortisone primary isolate: dichloromethane: methanol: water=1: 6.7~7.5: 1.6~2: 3~3.5; hydrocortisone crude product, dichloromethane Add methane, methanol, and water into the reaction tank according to the weight ratio, raise the temperature and reflux, lower the temperature, add a certain amount of water to dilute, and let it stand still. After two separation processes, the high-purity hydrocortisone is obtained after refining.
Owner:云南泽维制药有限公司
Grub enzymolysis primary isolate high in specific activity and preparation method of grub enzymolysis primary isolate
ActiveCN110343733AImprove antioxidant capacityHigh activityAntinoxious agentsPeptide preparation methodsHydrolysatePrimary isolate
The invention belongs to the field of agricultural biotechnology, and particularly relates to grub enzymolysis primary isolate high in specific activity and a preparation method of the grub enzymolysis primary isolate. The grub enzymolysis primary isolate is obtained through the following steps of separating grub enzymatic hydrolysate by adopting a sephadex column, and using ultra pure water as amobile phase; and collecting fraction at intervals. A high performance liquid chromatogram method is adopted for separating the grub lipase enzymolysis product, so that the obtained fraction has highoxidation resistance and specific activity.
Owner:FEED RESEARCH INSTITUTE CHINESE ACADEMY OF AGRICULTURAL SCIENCES
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com